Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Abstract

In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

Keywords

Affiliated Institutions

• Westmead Institute for Medical Research AU
• University of Wollongong AU
• Jacksonville Center for Clinical Research US
• Nova Scotia Health Authority CA
• University of Defence CZ
• The University of Queensland AU
• National Yang Ming Chiao Tung University TW
• Illawarra Health and Medical Research Institute AU
• Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana ES
• Deakin University AU
• Universidade Federal de São Paulo BR
• Barwon Health AU
• Health Sciences North CA
• Aichi Medical University JP
• Dalhousie University CA
• Uppsala University SE
• GlaxoSmithKline (Belgium) BE
• Stockholm County Council SE
• The University of Sydney AU
• United Christian Hospital HK
• Tampere University FI
• Taipei Veterans General Hospital TW
• University of Colorado Anschutz Medical Campus US
• Secretaría de Salud de Jalisco MX

Related Publications